Proxy-Reported Quality of Life and Access to Nusinersen Among Patients with Spinal Muscular Atrophy in Saudi Arabia

References

• Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Arch Neurol. 2011;68(8):979. doi:10.1001/archneurol.2011.74
   PubMedGoogle Scholar
• Tisdale S, Pellizzoni L. Disease mechanisms and therapeutic approaches in spinal muscular atrophy. J Neurosci. 2015;35(23):8691. doi:10.1523/JNEUROSCI.0417-15.2015
   PubMed Web of Science ®Google Scholar
• Oskoui MDB, DeVivo DC. Chapter 1. In: Sumner CJ, Paushkin S, Ko CP, editors. Spinal Muscular Atrophy: Disease Mechanisms and Therapy. London: Academic Press; Elsevier; 2017:3-17.
   Google Scholar
• Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155–165. doi:10.1016/0092-8674(95)90460-3
   PubMed Web of Science ®Google Scholar
• Matthew DM, John WH, Audrey CP, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002;4(1):20. doi:10.1097/00125817-200201000-00004
   Web of Science ®Google Scholar
• Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371(9630):2120–2133. doi:10.1016/S0140-6736(08)60921-6
   PubMed Web of Science ®Google Scholar
• Verhaart IE, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy–a literature review. Orphanet J Rare Dis. 2017;12(1):1–5. doi:10.1186/s13023-017-0671-8
   PubMed Web of Science ®Google Scholar
• Oskoui M, Darras BT, De Vivo DC. Spinal muscular atrophy: 125 years later and on the verge of a cure. In: Sumner CJ, Paushkin S, Ko C-P, editors. Spinal Muscular Atrophy: Disease Mechanisms and Therapy. San Diego, CA: Academic Press; 2017:3–19.
   Google Scholar
• Singh NN, Howell MD, Androphy EJ, Singh RN. How the discovery of Iss-N1 led to the first medical therapy for spinal muscular atrophy. Gene Ther. 2017;24(9):520–526. doi:10.1038/gt.2017.34
   PubMed Web of Science ®Google Scholar
• Messina S, Sframeli M. New treatments in spinal muscular atrophy: positive results and new challenges. J Clin Med. 2020;9(7):2222. doi:10.3390/jcm9072222
   PubMed Web of Science ®Google Scholar
• Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a Phase 2, open-label, dose-escalation study. Lancet Lond Engl. 2016;388:3017–3026. doi:10.1016/S0140-6736(16)31408-8
   PubMed Web of Science ®Google Scholar
• Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723–1732. doi:10.1056/NEJMoa1702752
   PubMed Web of Science ®Google Scholar
• Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625–635. doi:10.1056/NEJMoa1710504
   PubMed Web of Science ®Google Scholar
• Pechmann A, Langer T, Schorling D, et al. Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany. J Neuromuscul Dis. 2018;5:135–143. doi:10.3233/JND-180315
   PubMedGoogle Scholar
• Aragon-Gawinska K, Seferian AM, Daron A, et al. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: a cohort study. Neurology. 2018;91:1312–1318. doi:10.1212/WNL.0000000000006281
   PubMed Web of Science ®Google Scholar
• Pane M, Coratti G, Sansone VA, et al. Nusinersen in type 1 spinal muscular atrophy: twelve-month real-world data. Ann Neurol. 2019;86:443–451. doi:10.1002/ana.25533
   PubMed Web of Science ®Google Scholar
• Jochmann E, Steinbach R, Jochmann T, et al. Experiences from treating seven adult 5q spinal muscular atrophy patients with nusinersen. Ther Adv Neurol Disord. 2020;13:1756286420907803. doi:10.1177/1756286420907803
   Web of Science ®Google Scholar
• Zuluaga-Sanchez S, Teynor M, Knight C, et al. Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden. Pharmacoeconomics. 2019;37(6):845–865. doi:10.1007/s40273-019-00769-6
   PubMed Web of Science ®Google Scholar
• Thokala P, Stevenson M, Kumar VM, Ren S, Ellis AG, Chapman RH. Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Eff Resour Alloc. 2020;18(1):1–2. doi:10.1186/s12962-020-00234-8
   Web of Science ®Google Scholar
• Robertson D BIOGEN’S SPINRAZA®(nusinersen) receives recommendation from nice for the treatment of infants, children and adults with 5q spinal muscular atrophy. 2019.
   Google Scholar
• Ali I, Gilchrist FJ, Carroll WD, et al. Healthcare utilisation in children with SMA type 1 treated with nusinersen: a single centre retrospective review. BMJ Paediatr Open. 2019;3(1):e000572. doi:10.1136/bmjpo-2019-000572
   Google Scholar
• Kamusheva MS, Dimitrova MJ. Clinical and economic assessment of nusinersen: the bulgarian perspective. Expert Opin Orphan Drugs. 2020;8(10):403–415. doi:10.1080/21678707.2020.1835641
   Web of Science ®Google Scholar
• Ecker T, Leismann J. PBI31 managed entry agreements for ATMPs despite access already granted? The case of Germany. Value Health. 2020;23:S19. doi:10.1016/j.jval.2020.04.095
   Web of Science ®Google Scholar
• Day JW, Chiriboga CA, Crawford TO, et al. Onasemnogene abeparvovec-xioi gene-replacement therapy for spinal muscular atrophy type 1 (SMA1): phase 3 US study (STR1VE) update (1828). 2020.
   Google Scholar
• Alsaqa’aby MF, Ibrahim N. An overview about rare diseases in Saudi Arabia and reimbursement of orphan drugs. Glob J Med Therap. 2019;1(2):8–13.
   Google Scholar
• Landfeldt E, Edström J, Sejersen T, Tulinius M, Lochmüller H, Kirschner J. Quality of life of patients with spinal muscular atrophy: a systematic review. Eur J Paediatr Neurol. 2019;23(3):347–356. doi:10.1016/j.ejpn.2019.03.004
   PubMed Web of Science ®Google Scholar
• Whynes DK. Correspondence between EQ-5D health state classifications and EQ VAS scores. Health Qual Life Outcomes. 2008;6:94. doi:10.1186/1477-7525-6-94
   PubMed Web of Science ®Google Scholar
• Aburuz S, Bulatova N, Twalbeh M, et al. The validity and reliability of the Arabic version of the EQ-5D: a study from Jordan. Ann Saudi Med. 2009;29(4):304–308. doi:10.4103/0256-4947.55313
   PubMed Web of Science ®Google Scholar
• World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi:10.1001/jama.2013.281053
   PubMed Web of Science ®Google Scholar
• Lucas F. Improving market access to rare disease therapies: a worldwide perspective with recommendations to the industry. Med Access Point Care. 2018;2:2399202618810121. doi:10.1177/2399202618810121
   Google Scholar
• Belter L, Cruz R, Jarecki J. Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the Cure SMA community update survey. Orphanet J Rare Dis. 2020;15(1):1. doi:10.1186/s13023-020-01498-2
   Web of Science ®Google Scholar
• Audic F, de la Banda MG, Bernoux D, et al. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study. Orphanet J Rare Dis. 2020;15(1):1. doi:10.1186/s13023-020-01414-8
   Web of Science ®Google Scholar
• Jones TL, Baxter MA, Khanduja V. A quick guide to survey research. Ann R Coll Surg Engl. 2013;95(1):5–7. doi:10.1308/003588413X13511609956372
   PubMed Web of Science ®Google Scholar
• Bowling A. Mode of questionnaire administration can have serious effects on data quality. J Public Health (Bangkok). 2005;27(3):281–291. doi:10.1093/pubmed/fdi031
   PubMed Web of Science ®Google Scholar